ABSTRACT
Objective:
Contrast-induced nephropathy (CIN) is still a complication that causes serious morbidity and mortality in patients with acute coronary syndrome. Early identification of high-risk patients is of great importance in terms of prognosis. In our research, we intended to inquire the predicative value of Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) rating in the development of CIN in non-ST-segment elevation myocardial infarction (NSTEMI) patients undergoing percutaneous coronary intervention (PCI).
Material and Methods:
Patients hospitalized in the coronary intensive care unit with the diagnosis of NSTEMI and who underwent PCI were retrospectively included. The patients were divided into two groups according to the development of CIN, and the two groups were statistically compared according to clinical, demographic and laboratory findings. ATRIA and CHA2DS2-VASc scores of the patients were calculated.
Results:
In our research, an overall of 550 patients who underwent PCI for NSTEMI were involved. After PCI, CIN was seen in 78 (14.1%) patients. Diabetes, heart failure, and previous strokes were higher in the group with CIN. The ejection fraction was significantly lower in the group with CIN (p<0.0001). CHA2DS2-VASc and ATRIA scores were significantly higher in patients who developed CIN compared to those who did not (p<0.0001).
Conclusion:
We showed that a high ATRIA score has predictive value in the development of CIN in NSTEMI patients undergoing PCI. The high CHA2DS2-VASc score, which has been shown to be associated with the development of CIN in patients with acute coronary syndrome in previous studies, may provide additional information to estimate the incidence of CIN development in our study.
Keywords:
Contrast nephropathy, percutaneous coronary intervention, ATRIA, myocardial infarction
References
1
Tegn N, Abdelnoor M, Aaberge L, Endresen K, Smith P, Aakhus S, et al. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. Lancet 2016;387:1057-1065.
2
Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000;36(5):1542-1548.
3
Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105(19):2259-2264.
4
Kusirisin P, Chattipakorn SC, Chattipakorn N. Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches. J Transl Med 2020;18(1):400.
5
Chong E, Poh KK, Liang S, Tan HC. Risk factors and clinical outcomes for contrast-induced nephropathy after percutaneous coronary intervention in patients with normal serum creatinine. Ann Acad Med Singap 2010;39(5):374-380.
6
Yang Y, George KC, Luo R, Cheng Y, Shang W, Ge S, et al. Contrast-induced acute kidney injury and adverse clinical outcomes risk in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. BMC Nephrol 2018;19(1):374.
7
Çetinkal G, Koçaş C, Koçaş BB, Arslan Ş, Abacı O, Karaca OŞ, et al. Comparative performance of AnTicoagulation and Risk factors In Atrial fibrillation and Global Registry of Acute Coronary Events risk scores in predicting long-term adverse events in patients with acute myocardial infarction. Anatol J Cardiol 2018;20(2):77-84.
8
Kurtul A, Yarlioglues M, Duran M. Predictive Value of CHA2DS2-VASC Score for Contrast-Induced Nephropathy After Percutaneous Coronary Intervention for Acute Coronary Syndrome. Am J Cardiol 2017;119(6):819-825.
9
Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc 2013;2(3):e000250.
10
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137(2):263-272.
11
Sang W, Yang K, Li X, Xu F, Zhang J, Wu H, et al. [Early prevention progress of contrast induced nephropathy]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2019;31(9):1174-1178.
12
Fähling M, Seeliger E, Patzak A, Persson PB. Understanding and preventing contrast-induced acute kidney injury. Nat Rev Nephrol 2017;13(3):169-180.
13
Chalikias G, Tziakas DN. Contrast induced nephropathy an elusive disease entity - More questions than answers. Int J Cardiol 2019;290:77-78.
14
Heinrich MC, Kuhlmann MK, Grgic A, Heckmann M, Kramann B, Uder M. Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. Radiology 2005;235(3):843-849.
15
Caiazza A, Russo L, Sabbatini M, Russo D. Hemodynamic and tubular changes induced by contrast media. Biomed Res Int 2014;2014:578974.
16
McCullough PA, Stacul F, Becker CR, Adam A, Lameire N, Tumlin JA, et al. CIN Consensus Working Panel. Contrast-Induced Nephropathy (CIN) Consensus Working Panel: executive summary. Rev Cardiovasc Med 2006;7(4):177-197.
17
McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008;51(15):1419-1428.
18
Kelesoglu S, Yilmaz Y, Elcık D, Çetınkaya Z, Inanc MT, Dogan A, et al. Systemic Immune Inflammation Index: A Novel Predictor of Contrast-Induced Nephropathy in Patients With Non-ST Segment Elevation Myocardial Infarction. Angiology 2021;72(9):889-895.
19
Piller V, Jarlborg P, Morère PH. Néphropathie aux produits de contraste iodés : mythe ou réalité ? [Contrast induced nephropathy : myth or reality ?]. Rev Med Suisse 2019;15(635):206-210.
20
Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Wiviott SD. Short-term outcomes of acute myocardial infarction in patients with acute kidney injury: a report from the national cardiovascular data registry. Circulation 2012;125(3):497-504.
21
Parco C, Brockmeyer M, Kosejian L, Quade J, Tröstler J, Bader S, et al. National Cardiovascular Data Registry-Acute Kidney Injury (NCDR) vs. Mehran risk models for prediction of contrast-induced nephropathy and need for dialysis after coronary angiography in a German patient cohort. J Nephrol 2021;34(5):1491-1500.
22
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37(38):2893-2962.
23
Aspberg S, Chang Y, Atterman A, Bottai M, Go AS, Singer DE. Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation. Eur Heart J 2016;37(42):3203-3210.
24
van den Ham HA, Klungel OH, Singer DE, Leufkens HG, van Staa TP. Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database. J Am Coll Cardiol 2015;66(17):1851-1859.
25
Chaudhary AK, Pathak V, Kunal S, Shukla S, Pathak P. CHA2DS2-VASc score as a novel predictor for contrast-induced nephropathy after percutaneous coronary intervention in acute coronary syndrome. Indian Heart J 2019;71(4):303-308.
26
Tsai TT, Patel UD, Chang TI, Kennedy KF, Masoudi FA, Matheny ME, et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv 2014;7(1):1-9.
27
Baydar O, Kilic A. CHA2DS2-VASC Score Predicts Risk of Contrast-Induced Nephropathy in Non-ST Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Interventions. Kidney Dis (Basel) 2019;5(4):266-271.
28
Aksoy F, Bagcı A. Predictive value of ATRIA risk score for contrast-induced nephropathy after percutaneous coronary intervention for ST-segment elevation myocardial infarction. Rev Assoc Med Bras (1992) 2019;65(11):1384-1390.
29
Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 2006;(100):11-15.
30
Subramaniam RM, Suarez-Cuervo C, Wilson RF, Turban S, Zhang A, Sherrod C, et al. Effectiveness of Prevention Strategies for Contrast-Induced Nephropathy: A Systematic Review and Meta-analysis. Ann Intern Med 2016;164(6):406-416.
31
Hossain MA, Costanzo E, Cosentino J, Patel C, Qaisar H, Singh V, et al. Contrast-induced nephropathy: Pathophysiology, risk factors, and prevention. Saudi J Kidney Dis Transpl 2018;29(1):1-9.
32
Hong WY, Kabach M, Feldman G, Jovin IS. Intravenous fluids for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography and cardiac catheterization. Expert Rev Cardiovasc Ther 2020;18(1):33-39.
33
Li H, Wang C, Liu C, Li R, Zou M, Cheng G. Efficacy of Short-Term Statin Treatment for the Prevention of Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Angiography/Percutaneous Coronary Intervention: A Meta-Analysis of 21 Randomized Controlled Trials. Am J Cardiovasc Drugs 2016;16(3):201-219.
34
Attallah N, Yassine L, Musial J, Yee J, Fisher K. The potential role of statins in contrast nephropathy. Clin Nephrol 2004;62(4):273-278.
35
Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O’Donnell MJ, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005;118(8):843-849.
36
Iakovou I, Dangas G, Mehran R, Lansky AJ, Ashby DT, Fahy M, et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol 2003;15(1):18-22.